References
- Rosenmayr-Templeton L . Industry update. Therapeutic Delivery3(1), 9–15 (2012).
- Rosenmayr-Templeton L . Industry update. Therapeutic Delivery2(3), 291–296 (2011).
Websites
- Arrowhead Research Corp. Dynamic polyconjugates (DPC) technology: an elegant solution to the siRNA delivery problem. www.arrowres.com/pdf/Arrowhead-Research-Corporation_-_DPC-Technology-White-Paper-November2011.pdf
- Arrowhead Research Corp. Arrowhead Research publishes White Paper on RNAi delivery technology acquired from Roche. www.arrowres.com/publications/november7_2011.html
- Arrowhead Research Corp. Arrowhead Research lifts veil on recent progress in DPC delivery. http://rnaitherapeutics.blogspot.com/2011/11/arrowhead-research-lifts-veil-on-recent.html
- Former Ribopharma founders buy Roche‘s German RNA drugs site to launch services business. www.genomeweb.com/rnai/former-ribopharma-founders-buy-roches-german-rna-drugs-site-launch-services-busi
- Pfizer acquires Excaliard, an Isis spinout with drug to fight excessive scarring. www.xconomy.com/san-diego/2011/11/22/pfizer-acquires-excaliard-an-isis-spinout-with-drug-to-fight-excessive-scarring
- Pfizer completes acquisition of Excaliard. www.genengnews.com/industry-updates/pfizer-completes-acquisition-of-excaliard/136350381
- Mylan to acquire Pfizer respiratory delivery platform. http://investor.mylan.com/releasedetail.cfm?ReleaseID=622192
- Mylan to buy Pfizer‘s respiratory delivery platform. www.in-pharmatechnologist.com/Materials-Formulation/Mylan-to-buy-Pfizer-s-respiratory-delivery-platform
- Irreconcilable differences: Lilly and Amylin divorce. www.pharmalot.com/2011/11/irreconcilable-differences-lilly-amylin-get-divorced
- Amylin to pay Lilly $250M to end exenatide partnership and litigation. www.genengnews.com/gen-news-highlights/amylin-to-pay-lilly-250m-to-end-exenatide-partnership-and-litigation/81245926
- Alkermes keeps drug-delivery ties intact in Lilly-Amylin breakup. www.fiercedrugdelivery.com/story/alkermes-keeps-drug-delivery-ties-intact-lilly-amylin-breakup/2011-11-09
- Amylin and Eli Lilly part ways on diabetes drug; alkermes deal intact. www.xconomy.com/san-diego/2011/11/08/amylin-and-lilly-part-ways-agree-to-separation-agreement/
- Bend Research signs technology licensing agreement with Merck. www.prnewswire.com/news-releases/bend-research-signs-technology-licensing-agreement-with-merck-133794263.html
- Pfizer and Bend collaborating on osteoarthritis nanoparticle drug delivery. www.in-pharmatechnologist.com/Materials-Formulation/Pfizer-Bend-collaborating-on-osteoarthritis-nanoparticle-drug-delivery
- Royal DSM injects delivery tech into scar-reduction alliance. www.fiercedrugdelivery.com/story/royal-dsm-injects-delivery-tech-scar-reduction-alliance/2011-11-29
- Canadian Life Sciences Database: Adetherapeutics Inc. www.canadianlifesciences.com/ca/db/detail.php?c=5624451k$SnGKHKqJXxJw
- DSM and Svelte? Medical Systems, Inc. Execute license and supply agreement for DSM‘s proprietary amino acid based-drug carrier for Svelte‘s new all-in-one drug-eluting stent system. www.istockanalyst.com/business/news/5525085/dsm-and-svelte-medical-systems-inc-execute-license-and-supply-agreement-for-dsm-s-proprietary-amino-acid-based-drug-carrier-for-svelte-s-new-all-in-one-drug-eluting-stent-system
- Roche and Aileron pin third program to stapled peptide drug collaboration. www.genengnews.com/gen-news-highlights/roche-and-aileron-pin-third-program-to-stapled-peptide-drug-collaboration/81245960
- Aileron CEO hails expanded Roche deal as a validation of stapled-peptide drug technology. www.xconomy.com/boston/2011/11/17/aileron-ceo-hails-expanded-roche-deal-as-a-validation-of-stapled-peptide-drug-technology
- Hot Ablynx antibody tech earns $69M discovery pact with Merck Serono. www.fiercebiotech.com/story/hot-ablynx-antibody-tech-earns-69m-discovery-pact-merck-serono/2011-11-09
- Cancer vax developer NewLink Genetics‘ IPO nets $43.4M. www.fiercebiotech.com/story/cancer-vax-developer-newlink-genetics-ipo-nets-434m/2011-11-11
- NewLink Genetic‘s 6.2M Share IPO prices At $7. http://online.wsj.com/article/BT-CO-20111111-706594.html
- Avaxia pulls in $2M from Angels to fund development of cow-derived drug. www.xconomy.com/boston/2011/11/15/avaxia-pulls-in-2m-from-angels-to-fund-development-of-cow-derived-drug
- Leonardo Biosystems receives second $1.25 million investment from the Texas Emerging Technology Fund. www.genengnews.com/industry-updates/leonardo-biosystems-receives-second-1-25-million-investment-from-the-texas-emerging-technology-/134670304
- FDA pins approval on new formulation of Ambien. www.fiercedrugdelivery.com/story/fda-pins-approval-new-formulation-ambien/2011-11-29
- Boston Scientific receives FDA approval for Promus Element™ Plus Platinum Chromium Stent System. www.multivu.com/mnr/43510-boston-scientific-fda-promus-element-plus-platinum-chromium-stent-system
- FDA accepts Otsuka‘s app for long-lasting Abilify. www.fiercedrugdelivery.com/story/fda-accepts-otsukas-app-long-lasting-abilify/2011-11-22
- New drug application for Otsuka‘s once-monthly Aripiprazole depot formulation for maintenance treatment of adult patients with schizophrenia accepted for review by the US Food and Drug Administration. www.genengnews.com/industry-updates/new-drug-application-for-otsuka-s-once-monthly-aripiprazole-depot-formulation-for-maintenance-tr/135478191
- Affymax investors bullish on FDA review of Amgen anemia drug rival. www.fiercebiotech.com/story/affymax-investors-bullish-fda-review-amgen-anemia-drug-rival/2011-12-05
- Affymax shares climb as FDA considers wider use for Anemia drug. www.xconomy.com/san-francisco/2011/12/05/affymax-shares-climb-as-fda-considers-wider-use-for-anemia-drug
- Alimera, pSivida shares take a beating on FDA‘s Iluvien rejection. www.fiercebiotech.com/story/alimera-psivida-shares-take-beating-fdas-iluvien-rejection/2011-11-14
- Unigene announces Novartis‘ disclosure of first interpretable results from Phase III trial of calcitonin (SMC021) in the treatment of post-menopausal osteoporosis. www.genengnews.com/industry-updates/unigene-announces-novartis-disclosure-of-first-interpretable-results-from-phase-3-trial-of-calc/134667109
- Novartis falls short in trial for oral osteoporosis drug. www.fiercedrugdelivery.com/story/novartis-falls-short-trial-oral-osteoporosis-drug/2011-11-16
- Turnaround CEO shores up strategy for Unigene based on big pharma partnerships. www.xconomy.com/new-york/2011/11/15/turnaround-ceo-shores-up-strategy-for-unigene-based-on-big-pharma-partnerships
- Unigene announces positive top-line results of Phase II oral PTH study for the treatment of osteoporosis in postmenopausal women. www.medicalnewstoday.com/releases/237413.php
- Unigene regains oral rPTH osteoporosis candidate from GSK. www.genengnews.com/gen-news-highlights/unigene-regains-oral-rpth-osteoporosis-candidate-from-gsk/81246029
- Stem cell trial halted. www.bbc.co.uk/news/health-15740133
- AlloCure stem cell trial provides glimpse of promising treatment for kidney damage. www.xconomy.com/boston/2011/11/18/allocure-stem-cell-trial-provides-glimpse-of-promising-treatment-for-kidney-damage
- Positive results from Phase II trial of Mesoblast‘s adult stem cell therapy presented at the American Heart Association Annual Meeting. www.genengnews.com/industry-updates/positive-results-from-phase-2-trial-of-mesoblast-s-adult-stem-cell-therapy-presented-at-the-amer/134717039
- GSK‘s albiglutide flunks head-to-head diabetes PhIII with rival Victoza. www.fiercebiotech.com/story/gsks-albiglutide-flunks-head-head-diabetes-phiii-rival-victoza/2011-11-16
- GSK receives initial data from the first completed phase III study of albiglutide in type 2 diabetes. www.fiercebiotech.com/press-releases/gsk-receives-initial-data-first-completed-phase-lll-study-albiglutide-type-
- CODHy: Diabetes docs await weekly GLP-1 mimics. www.medpagetoday.com/MeetingCoverage/CODHy/20182
- Amgen. Enbrel® (etanercept) patent issued. www.amgen.com/media/media_pr_detail.jsp?releaseID=1633115
- Amgen patent ploy undercuts healthcare law. http://feedproxy.google.com/~r/Pharmalot/~3/Bvd0fqUGz_I
- Amgen‘s new Enbrel patent could delay biosims for 17 years. www.fiercepharma.com/story/amgens-new-enbrel-patent-could-delay-biosims-17-years/2011-11-23
- Amgen‘s new patent: explanations, anyone? http://pipeline.corante.com/archives/2011/11/28/amgens_new_patent_explanations_anyone.php
- Santaris Pharma says USPTO upholds key antisense patents. www.genomeweb.com/rnai/santaris-pharma-says-uspto-upholds-key-antisense-patents
- Santaris pharma. United States Patent and Trademark Office upholds key Santaris Pharma A/S LNA patents in two re-examination cases brought by Isis Pharmaceuticals. www.santaris.com/news/2011/11/30/united-states-patent-and-trademark-office-upholds-key-santaris-pharma-lna-patents-tw